GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (LSE:PXS) » Definitions » EBITDA Margin %

Provexis (LSE:PXS) EBITDA Margin % : -18.85% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Provexis EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Provexis's EBITDA for the six months ended in Sep. 2024 was £-0.15 Mil. Provexis's Revenue for the six months ended in Sep. 2024 was £0.79 Mil. Therefore, Provexis's EBITDA margin for the quarter that ended in Sep. 2024 was -18.85%.


Provexis EBITDA Margin % Historical Data

The historical data trend for Provexis's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis EBITDA Margin % Chart

Provexis Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -122.13 -71.68 -70.19 -107.95 -75.31

Provexis Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.21 -117.06 -71.13 -78.99 -18.85

Competitive Comparison of Provexis's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provexis's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Provexis's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Provexis's EBITDA Margin % falls into.


;
;

Provexis EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Provexis's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-0.604/0.802
=-75.31 %

Provexis's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.148/0.785
=-18.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provexis  (LSE:PXS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Provexis EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Provexis's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Provexis Business Description

Traded in Other Exchanges
Address
2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.